EP Patent

EP1550471A1 — Intraocular implants for preventing transplant rejection in the eye

Assigned to Allergan Inc · Expires 2005-07-06 · 21y expired

What this patent protects

An intraocular biodegradable drug delivery system comprising a steroidal anti-inflammatory agent mixed with a bioerodible polymer is useful for preventing or reducing neovascularizsation in an eye prone to neovascularization.

USPTO Abstract

An intraocular biodegradable drug delivery system comprising a steroidal anti-inflammatory agent mixed with a bioerodible polymer is useful for preventing or reducing neovascularizsation in an eye prone to neovascularization.

Drugs covered by this patent

Patent Metadata

Patent number
EP1550471A1
Jurisdiction
EP
Classification
—
Expires
2005-07-06
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.